Celestica Inc vs Novo Nordisk A/S — how do they compare? Celestica Inc trades at $335.9 (market cap $39.16B), while Novo Nordisk A/S trades at $46.27 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.3× Celestica Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| CLS | NVO | |
|---|---|---|
Market Cap | $39.16B | $207.85B |
Sector | Technology | Health |
52-Week High | $472.40 | $63.98 |
52-Week Low | $181.34 | $35.29 |
Enterprise Value | $39.44B | $222.55B |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
CLS trades at $336.97, up 7.11% on the day, with a bearish technical signal from moving averages but strong fundamental performance. The company reported three consecutive quarterly EPS beats, with Q2 2026 actual EPS of $2.54 exceeding the $2.29 estimate. Revenue for 2025 was $12.39 billion, with a net income margin of 7.16% and robust ROE of 52.69%. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, alongside new contracts with key tech partners.
The outlook is supported by accelerating AI-driven demand and raised guidance, but near-term dilution from the equity raise poses a risk. Analyst consensus is strongly bullish with a $466.50 price target, though the stock's premium valuation requires careful monitoring of execution against growth expectations.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Trailing returns across standard periods
Latest headlines on both assets
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →